21-hydroxylase deficiency overview

Revision as of 20:32, 4 September 2015 by Ahmad Al Maradni (talk | contribs)
Jump to navigation Jump to search

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

21-hydroxylase deficiency overview On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of 21-hydroxylase deficiency overview

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on 21-hydroxylase deficiency overview

CDC on 21-hydroxylase deficiency overview

21-hydroxylase deficiency overview in the news

Blogs on 21-hydroxylase deficiency overview

Directions to Hospitals Treating Congenital adrenal hyperplasia due to 21-hydroxylase deficiency

Risk calculators and risk factors for 21-hydroxylase deficiency overview

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Cafer Zorkun, M.D., Ph.D. [2]

Overview

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency (21-OH CAH), in all its forms, accounts for about 95% of diagnosed cases of congenital adrenal hyperplasia, and CAH in most contexts refers to 21-hydroxylase deficiency.

Historical Perspective

Congenital adrenal hyperplasia was first discovered by Luigi De Crecchio, an Italian anatomist.

Pathophysiology

Development of congenital adrenal hyperplasia is the result of multiple enzymatic deficiencies.

Causes

In general congenital adrenal hyperplasia may be caused by either 21-hydroxylase deficiency, 11-β hydroxylase deficiency or 17-α hydroxylase deficiency.

Differentiating congenital adrenal hyperplasia due to 21-hydroxylase deficiency from other diseases

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency must be differentiated from other causes of adrenal hyperplasia such as 11-β hydroxylase deficiency and 17-α hydroxylase deficiency.

Epidemiology and Demographics

The incidence of 21-hydroxlase deficient congenital adrenal hyperplasia is approximately 1 per 15,000 birth.

Risk Factors

The most potent risk factor in the development of 21-hydroxylase deficient congenital adrenal hyperplasia is Mutations in the CYP21A2 gene.

Screening

Natural History

The prognosis of 21-hydroxylase deficient congenital adrenal hyperplasia is generally good with treatment. Common complications of 21-hydroxylase deficient congenital adrenal hyperplasia include Adrenal crisis, Infertility, and precocious puberty.

History and Symptoms

Symptoms of 21-hydroxylase deficient congenital adrenal hyperplasia include dehydration, vomiting and weight loss, symptoms occur later may include virilization and infertility

Physical Examination

Patients with 21-hydroxylase deficient congenital adrenal hyperplasia usually appear underweight and dehydrated. Physical examination of patients with 21-hydroxylase deficient congenital adrenal hyperplasia is usually remarkable for hypotension and virilization.



References


Template:WikiDoc Sources